Q32 Bio Inc has a consensus price target of $72.33 based on the ratings of 6 analysts. The high is $100 issued by Guggenheim on June 17, 2024. The low is $45 issued by Piper Sandler on April 2, 2024. The 3 most-recent analyst ratings were released by Raymond James, Wells Fargo, and Guggenheim on October 24, 2024, September 11, 2024, and June 17, 2024, respectively. With an average price target of $95 between Raymond James, Wells Fargo, and Guggenheim, there's an implied 286.97% upside for Q32 Bio Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Q32 Bio (NASDAQ:QTTB) was reported by Raymond James on October 24, 2024. The analyst firm set a price target for $90.00 expecting QTTB to rise to within 12 months (a possible 266.60% upside). 6 analyst firms have reported ratings in the last year.
The latest analyst rating for Q32 Bio (NASDAQ:QTTB) was provided by Raymond James, and Q32 Bio initiated their strong buy rating.
There is no last upgrade for Q32 Bio
There is no last downgrade for Q32 Bio.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Q32 Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Q32 Bio was filed on October 24, 2024 so you should expect the next rating to be made available sometime around October 24, 2025.
While ratings are subjective and will change, the latest Q32 Bio (QTTB) rating was a initiated with a price target of $0.00 to $90.00. The current price Q32 Bio (QTTB) is trading at is $24.55, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.